Madrigal’s Rezdiffra Shows Promising Two‑Year Data in F4c MASH Cirrhosis Efforts

Madrigal Pharmaceuticals continues to build evidence supporting its liver disease drug **Rezdiffra** (resmetirom), showcasing encouraging **two‑year open‑label data** in patients with **compensated MASH cirrhosis (F4c)** — a serious stage of metabolic dysfunction‑associated steatohepatitis that currently has no approved therapies. In the MAESTRO‑NAFLD‑1 trial’s F4c arm, treatment with Rezdiffra led to significant improvements in key liver biomarkers, including reductions in liver stiffness (a surrogate for fibrosis), fibrosis markers, and portal hypertension risk scores, compared with baseline measures. Patients also experienced better disease‑specific quality of life, with sustained effects over two years. Analyses indicate that interruptions in therapy reversed earlier benefits, which were regained upon resuming treatment, underscoring the importance of continued therapy in this advanced patient group. Madrigal currently holds a “Strong Buy” analyst rating supported by robust Rezdiffra sales and the ongoing effort to expand the drug’s indication into F4c cirrhosis via a pivotal outcomes trial expected to report data by 2027. #Rezdiffra #MASHCirrhosis #Madrigal #LiverDiseaseResearch #SlimScan #GrowthStocks #CANSLIM